CONNECT WITH US
HealthTech

HealthTech

Single iron infusion improved exercise capacity in people with the most common form of heart failure

Medical Xpress logo

Published on

Add as a preferred source on Google
Single iron infusion improved exercise capacity in people with the most common form of heart failure

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A new study by investigators from the Mass General Brigham Heart and Vascular Institute found that a single iron infusion improved exercise capacity in people with heart failure with preserved ejection fraction (HFpEF) and iron deficiency. The findings suggest that replenishing iron could help address the physical limitations associated with this condition. Results were presented at the 2026 American Heart Association Scientific Sessions and published simultaneously in Circulation.

The IRON-MET HFpEF trial enrolled 65 participants with symptomatic HFpEF and iron deficiency, which affects more than 50% of patients with HFpEF. Their median age was 68 years, and 72% of participants were women. Forty-four participants were randomized to receive one 1,000-mg IV dose of ferric derisomaltose and 21 to receive placebo. Iron was administered intravenously because previous studies have demonstrated that oral iron is not beneficial in patients with other forms of heart failure, likely due to poor gastrointestinal absorption.

All participants underwent cardiopulmonary exercise testing before and 12 weeks after the infusion. At 12 weeks, peak oxygen uptake, or VO₂—which is a key indicator of cardiorespiratory fitness—improved by approximately 10% in the intervention group and was unchanged in the placebo group.

"Patients living with HFpEF are burdened with severe limitations in exercise tolerance," said lead author Gregory D. Lewis, director of heart failure at the Mass General Brigham Heart and Vascular Institute and professor of medicine at Harvard Medical School.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.